Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Maurizio Galderisi,
Discover the details of the session
As a result of significant advances in cancer treatment in the last decade, many patients with cancer are now living with sufficient survival to develop the cardiovascular complications of their cancer treatment. There is a growing body of data describing the magnitude of risk of adverse cardiovascular events in the population of patients that received cancer treatment either in childhood, or as adults.
In the lecture by Bonnie Ky, (Philadelphia, USA) the audience learned that the risk of cardiotoxicity is associated with age, obesity/overweight, arterial hypertension and a reduced ejection fraction at baseline. Echocardiography is the most widely used imaging modality in the evaluation of these patients.
The monitoring of cardiotoxicity using imaging (addressed by M. Scherrer-Crosbie, Boston, USA) actually corresponds to the estimation of the ejection fraction, which is an imperfect index when using 2D echocardiography. At the present time, a reduction of ejection fraction > 10% is an indication to withdraw chemotherapy. The use of a contrast agent for better detection of endocardial borders can be considered to improve the “true” estimation of ejection fraction in the case of suboptimal images.
3D echocardiography should be preferred when available. However, early subclinical heart involvement induced by chemotherapy (as outlined by Thor Edvardsen) can be detected by estimating global longitudinal strain by Speckle Tracking Echocardiography. A value of global longitudinal strain lower than -19% is an accurate indicator of left ventricular systolic dysfunction and should be carefully taken into account.
Furthermore, radiotherapy also induces cardiotoxicity (as explained by B Cosyns, Belgium). Indeed, pericardial involvement (30% of the cases), wall motion abnormalities due to significant coronary artery stenosis, left ventricular systolic and/or diastolic dysfunction as well as valve heart disease (19-26%) can be identified by using echocardiography.
Lastly, as outlined by R Wassmuth (Berlin, Germany), cardiac magnetic resonance imaging can be very useful to obtain greater accuracy in the estimation of ejection fraction and also to detect late gadolinium enhancement.
Cancer treatments and cardiotoxicity: too much or too little?
European Society of Cardiology
European Heart HouseLes Templiers2035 Route des CollesCS 80179 BIOT
06903Sophia Antipolis, FR
© 2017 European Society of Cardiology. All rights reserved